home / stock / soltf / soltf quote
Last: | $9.30 |
---|---|
Change Percent: | 0.0% |
Open: | $9.2268 |
Close: | $9.30 |
High: | $9.3 |
Low: | $9.2268 |
Volume: | 1,465 |
Last Trade Date Time: | 04/26/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$9.3 | $9.2268 | $9.3 | $9.3 | $9.2268 | 1,465 | 04-26-2024 |
$9.72 | $9.72 | $9.72 | $9.72 | $9.72 | 100 | 04-16-2024 |
$10.44 | $10.44 | $10.44 | $10.44 | $10.44 | 300 | 04-08-2024 |
$9.99 | $10.175 | $9.99 | $10.175 | $9.99 | 1,000 | 04-03-2024 |
$10.8 | $10.59 | $10.8 | $10.8 | $10.59 | 400 | 04-01-2024 |
$10.526 | $10.526 | $10.526 | $10.526 | $10.526 | 3 | 03-18-2024 |
$10.7461 | $10.7461 | $10.7461 | $10.7461 | $10.7461 | 465 | 03-13-2024 |
$13.43 | $11.88 | $13.43 | $13.43 | $11.71 | 50,102 | 03-11-2024 |
$9.8844 | $9.8844 | $9.8844 | $9.8844 | $9.8844 | 25 | 03-05-2024 |
$9.875 | $9.875 | $9.875 | $9.875 | $9.875 | 20 | 03-04-2024 |
$9.9 | $9.9 | $9.9 | $9.9 | $9.9 | 100 | 02-29-2024 |
$8.72 | $8.72 | $8.72 | $8.72 | $8.72 | 100 | 02-19-2024 |
$8.72 | $8.72 | $8.72 | $8.72 | $8.72 | 100 | 02-16-2024 |
$8.65 | $8.56 | $8.65 | $8.715 | $8.56 | 1,500 | 02-15-2024 |
$9.5 | $9.5 | $9.5 | $9.5 | $9.5 | 500 | 02-14-2024 |
$9.554 | $9.554 | $9.554 | $9.554 | $9.554 | 100 | 02-05-2024 |
$9.822 | $9.81 | $9.822 | $9.822 | $9.75 | 300 | 01-29-2024 |
$9.5706 | $9.5706 | $9.5706 | $9.5706 | $9.5706 | 25 | 01-26-2024 |
$10.89 | $10.5 | $10.89 | $10.89 | $10.5 | 2,303 | 01-10-2024 |
$10.5 | $10.5 | $10.5 | $10.5 | $10.5 | 200 | 01-08-2024 |
News, Short Squeeze, Breakout and More Instantly...
Sosei Co Ltd Ord Company Name:
SOLTF Stock Symbol:
OTCMKTS Market:
Tokyo, Japan and Cambridge, UK, 17 April 2024 – Nxera Pharma Co. Ltd (“Nxera” or “the Company; TSE 4565) – formerly known as Sosei Group or Sosei Heptares – announces that it has decided to issue new shares (“the Share Issuance”) under the...
NBI-1117568 is an oral, selective muscarinic M4 receptor agonist advancing through Phase 2 clinical development under a multi-program collaboration with Neurocrine Biosciences Successful completion of a long-term preclinical toxicity program to support safe, chronic dosing of NBI-1117568 in f...
PIVLAZ™ is the first drug approved in South Korea for the prevention of Cerebral Vasospasm in patients with Aneurysmal Subarachnoid Hemorrhage (aSAH) PIVLAZ™ will become commercially available in South Korea in early 2025 Tokyo, Japan and Cambridge, UK, 1 5 April...